Authors


Bioforumis

Latest:

Digital Medicine and Pharma: The Partnerships Bringing Together Molecule and Software

Pharmaceutical Executive, in collaboration with Biofourmis, organized a roundtable of experts from various groups to discuss how digital medicine and pharmaceuticals are changing the trajectory of what drug development and clinical care look like together, with an emphasis on partnerships within digital health.


Salesforce

Latest:

Transforming Healthcare Data to Precision Medicine

A modern healthcare ecosystem involves various stakeholders and many forms of complex data. Collaborations and a range of advanced approaches are essential to providing more uniform and complete healthcare to patients.


Genpact

Latest:

The future of life sciences and healthcare v2

Genpact’s latest report, Life Sciences and Healthcare in the Age of Instinct, explores three major trends shaping the future of healthcare.


Ailsa Budden

Latest:

No Half Measures: How Medical Affairs Can Maximize and Measure Value

Education and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.


Amy Niles

Latest:

The Quest to Fully Address Prescription Drug Affordability

The Medicare Part D cap won’t solve need for financial assistance.



Adam Schoen, JD

Latest:

IP and Capital

Treat patents as strategic business assets and build an IP portfolio.


Dr. Ben Green

Latest:

The Rapid Growth of Remote Patient Monitoring Solutions Can Accelerate Decentralized Clinical Trials

Pharma companies and RPM manufacturers must work together to find solutions to make DCT more commonly available.


Joe Rossi IV

Latest:

Biopharma Needs a Health System Strategy to Secure Optimal Market Access

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.


Dan Fitzgerald

Latest:

How Good is a Good Product Launch?

A fresh look at how industry benchmarks can help fortify new drug launches to overcome today’s new market-entry barriers and higher expectations.


Venkatraman “Bala” Balasubramanian, PhD

Latest:

Using GenAI as a Co-Pilot for Regulatory Intelligence

GenAI is on the precipice of breaking new ground in regulatory intelligence; making strategists more efficient by alleviating challenges, streamlining regulatory research and submission processes.


Dean Mastrojohn

Latest:

Silver Linings of a Global Health Crisis: A New Path Forward for Pharma Media Professionals

at some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?


Chad A. Landmon, JD

Latest:

IP and Collaboration

Fighting the pandemic with joint projects and IP sharing.


David Ehrlich

Latest:

Industry Predictions For 2023

Top industry experts weigh in on what the new year holds for the pharma industry.


Girisha Fernando

Latest:

Instead of Drug Spending Caps, Medicare Should Try Value-Based Contracting

New regulations may require regulators to explore new payment options.


Crosstree

Latest:

Precision & Specialty Medicine Clinical Trials

Precision & Specialty Medicines are driving changes in the pharma development industry. We explore the changes these paradigms are having on the clinical trial space.


Catherine Tak Piech

Latest:

Shining a Light on Rare Disease: Evidence Challenges and Solutions

Significant challenges still lie ahead, but several specialists and a plethora of new technologies are well positioned to gather and analyze the evidence needed for diagnosing and treating rare diseases, writes Catherine Tak Piech.


David Kreutter

Latest:

Competing in Commercial Pharmaceuticals: Get Formal and Familiar with Analytics

Exploring the importance of analytics as a means of staying competitive in the commercial pharmaceutical market.



Bianca Anghelina

Latest:

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.


Jim Williams

Latest:

Four Critical Considerations for Launching Digital Diagnostic Tools

Creating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.



Diane Stephenson

Latest:

Open Science and Digital Health: A Brighter Future for Parkinson’s Disease

Collaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.


J. Kevin McHugh

Latest:

What Makes for a Great Leader in Pharma, and How to Hire One

A look into the traits that hiring managers of pharma companies should be searching for when hiring for a leadership role.


Alena Galante

Latest:

Virtual Medical Affairs Audits: A Viable Alternative

Virtual audits proving to be beneficial post-COVID despite continuing challenges.


Dan Schroen, Brand Insights Contributor, Head of Photo 51, a Fingerpaint company

Latest:

3 Steps to Supercharge Your Rare Disease Advocacy Partnerships

How these actions can help brand teams form effective and sustainable relationships with patient communities


Sam Murphy

Latest:

More Than a Trend: Steps to Ensure Patient-Centered Research Stays at the Forefront of Pharma

Pharma companies are now under increasing pressure, and increasingly willing, to offer a patient-centric approach. But with this increasing demand comes confusion about what patient-centered research actually is. 


Jonathan Olsen

Latest:

The Architecture of Global, Scalable, Next-Generation Patient Support Programs

Patient support programs (PSPs) have an opportunity for growth and innovation.


Sonja Foster-Storch

Latest:

Tapping NPs and PAs in Life Sciences Marketing

Amid the shifting focus from primary care to specialty care, using data-driven tactics can create tailored campaigns and meaningful relationships with nurse practitioners and physician assistants.


James Nyssen and Matt Gallant

Latest:

The Shifting Landscape of the Life Sciences Job Market

Planning for a post-recession scenario is essential, ensuring companies are prepared to scale up when funding permits.